Loading…
← CockpitCompetitor Analysis › 000650.SZ Renhe Pharmacy Co., Ltd. Class AOpen in the cockpit ↗

Renhe Pharmacy Co., Ltd. Class A000650.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.

Momentum strong 74
Mkt cap
$1.01B
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$11.5M
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
+5.0 pp
WACC 7.2%
Hurdle
-4 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥4.90
1D-0.6%
1W-2.8%
1M-4.5%
3M-10.9%
6M-12.0%
YTD-13.3%
1Y-21.6%
ATR %1.8%
52w lowhigh23.6% off high

What Renhe Pharmacy does

Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.

Earns its money from branded over-the-counter medicines, bought without a prescription, sold in volume through distributors and pharmacy chains and kept visible by heavy brand promotion. Traditional Chinese medicines make up a large part of drug sales, and eye drops and cold remedies are the best-known brands. A health-products line is being built beside the drugs.

Products and services

  • Cold and fever remedies (Kelike, Youkadan)
  • Shanliang eye drops
  • Traditional Chinese medicines (Dahuoluo capsules and others)
  • Fuyanjie feminine-care products
  • Health and personal-care products

Customers

  • Pharmacy chains and retailers
  • Pharmaceutical distributors
  • Consumers buying over the counter

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • OTC drugs and consumer health

What could go right

  • Eye-care and respiratory brand push
  • Expanding health and personal-care products

What could go wrong

  • Advertising and product-quality scrutiny
  • Crowded OTC brand competition

Moat: narrow (brand, distribution). Long-established OTC brands and a nationwide sales network; little patent protection and heavy advertising reliance.

Headquarters: Nanchang, China

Named competitors

Renhe Pharmacy at a glance

Size Renhe Pharmacy (000650.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.01B, the 2134th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.90 on 18 Nov 2026.

Performance Over six months the shares fell 12.0%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 7.0% over the last twelve months (peer median +7.7%); the operating margin is 14.3% (peer median 8.7%).

Valuation It trades at 16.9× forward earnings against a peer median of 20.6× (7th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.0 points above its cost of capital (7.2% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 92000650.SZ 89
Six months, rebased to 100: Renhe Pharmacy against the median of its 20 peers (local-currency closes).

Renhe Pharmacy financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.49Bn/aCN¥4.05BCN¥5.00BCN¥5.12B
Revenue growth——-19%-2%—
Gross profitCN¥1.33Bn/an/aCN¥1.78BCN¥1.78B
EBITDAn/an/an/aCN¥1.09BCN¥1.00B
Net incomeCN¥386Mn/aCN¥482MCN¥567MCN¥574M
Free cash flowCN¥488Mn/an/aCN¥391MCN¥1.09B
Capital expenditureCN¥47.8Mn/an/aCN¥187MCN¥221M
Total debtCN¥2.22Mn/an/aCN¥18.5MCN¥34.4M

Quarterly statements and history in the cockpit →

Renhe Pharmacy competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%48873007023004976880916885136051166887104553002737600557SVRABSLNAARTIPHARM688382600129SPTXBLUEJETPGHL1952000650.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Renhe Pharmacy is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×20×40×60×48873007023004976885136051166887104553002737BSLN600129BLUEJET1952000650.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Renhe Pharmacy is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%3007023004976885136051166887104553002737BSLN688382BLUEJET000650.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Renhe Pharmacy is the large dot.

Renhe Pharmacy competitors and peer comparison

Head to head with its named competitors (000650.SZ vs 000999.SZ vs 600750.SS vs 600129.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Renhe Pharmacy 000650.SZ$1.01B-12%-7%14%16.9×-10.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
China Resources Jiangzhong Pharmaceutical 600750.SS$2.27B+4%-10%24%16.5×-1.9%
Chongqing Taiji Industry (Group) 600129.SS$982M-20%-4%2%69.8×n/a
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Renhe Pharmacy compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Renhe Pharmacy against its 20 peers (data as of 18 Nov 2026)
Measure000650.SZPeer medianRank in peer set
1-month return-4.5%-6.0%8th highest of 21
6-month return-12.0%-10.6%10th lowest of 21
Distance from 52-week high-23.6%-32.4%6th highest of 21
Revenue growth (TTM)-7.0%+7.7%3rd lowest of 19
Operating margin14.3%8.7%7th highest of 19
Forward P/E16.9×20.6×7th cheapest of 15
Growth the price implies (Req g, 7 yrs)-10.7%4.3%least demanding of 14
Growth delivered (Del g)-7.0%+7.7%3rd lowest of 14
Hurdle (Req g minus delivered)-3.6 pp-3.3 pp7th least demanding of 14
ROIC minus cost of capital+5.0 pp+0.1 pp5th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a

Questions

Who are Renhe Pharmacy's main competitors?
Named competitors: China Resources Sanjiu (000999.SZ), Jiangzhong Pharmaceutical (600750.SS), Taiji Group (600129.SS), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes SAWAI (4887.T), Zhejiang Tianyu Pharmaceutical (300702.SZ), Jiangxi Fushine Pharmaceutical (300497.SZ), Shanghai Yizhong Pharmaceutical (688091.SS), Chengdu Easton Biopharmaceuticals (688513.SS), Aurisco Pharmaceutical (605116.SS).
Is Renhe Pharmacy expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 20.6×, 7th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Renhe Pharmacy stock performed?
Over six months to 18 Nov 2026 the shares returned -12.0% against -10.6% for the median peer; over one year -21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.